you, Thank Tom.
Our growth strategy efforts. on is built core X
The in first grow and the is establish U.S. Quell to market. indication fibromyalgia the
recent The DPNCheck additional the Medicare And revise changes second to an on I business will now Advantage. advance for the program, comment to strategy to each and addressable of which lead to is is activities. the market. Quell will Neurotherapeutics third account indications expanded the these in
and proprietary First stimulation with multi-hour electrical our chronic It and based treatment platform. respect to syndromes. of pain wearable has the as FDA lower device first received indicated is on relief fibromyalgia neuromodulation help It is for daily nerve symptoms pain wearable technology for transcutaneous our adaptive calls reduce and authorization Quell novo is only of the only chronic de to neuromodulation fibromyalgia. extremity the FDA-cleared
efforts commercialization the This focused up the a chronic available indication on syndrome prescription in latter is At Fibromyalgia indication. XX are this pain that only. affects is fibromyalgia U.S. to time, complex people exclusively our million by
are is need which safe additional treatments. for The critical side can a pregabalin, duloxetine substantial and unmet only milnacipran, drugs have FDA-approved effects. There
processing cohorts time, third identify are the the and deliberate strategic marketing prescription effectiveness the is our The that the the solution intended of and quarter of third At optimize this to for clinical was solution. patient commercial in launch Quell year this phase of we refine our most attractive messaging fibromyalgia. of quarter to a to
to and the regional consists team with X our and we quarter on of Our second national coverage Texas business and preliminary which a sales XXXX. managers, expect expansion California of Florida, us provide in director decide of commercial next the markets,
national with is refills. Quell and available to this online a partnered initial a At prescriptions fulfill time, fibromyalgia basis. have pharmacy both We cash-pay on
second to specialists of over unique the filled second The XXX XXX to medicine common quarter. increased then quarter of pain are XX% third by quarter, There number the fibromyalgia quarter third in with neurologists. The prescriptions prescribers Quell XXX during that most prescriptions have in the compared been prescribers of patients. XXX rheumatologists, and during cumulative the from
The we our almost are Quell Overall, QX the in month with third early doubled refills with quarter. number cumulative commercial from fibromyalgia. experience pleased to of in XXX XXX
expect see to material revenue to leading progress in continued We XXXX.
to program. neurotherapeutics broader Quell on our Moving
As the for the of as people X treatment for growth chronic many peripheral element mentioned, indication. develop Quell the beyond CIPN, chemotherapy-induced every receive chemotherapy who year. that of or second to pipeline affects along initial approximately the fibromyalgia million which neurotherapeutics furthest is I is our strategy XX% program as is The of neuropathy,
pilot the at FDA Rochester. the chronic in on CIPN multicenter enrollment opportunity -- the and of sham-controlled A review treating double-blinded randomized and for now indication. last University that quarter study debilitating a Quell sham-controlled in side determined of trial breakthrough and CIPN have they have results January for is a the we clinical NIH-funded cancer conducted designation to of third Quell XXXX FDA modern-to-severe based support received filing completed a treatment. year, It effect of XXX(k) had
and quarter Depending ultimate on be initialize or of XXXX. latest. -- next We line FDA the the since this commercialization at the time positioned could have review the funded the that be must in But we results completed was FDA. NIH, we believe quarter year the largely end occurs the to initiate the wait to that before study clearance submission first We published documents. decision, for we this by data of to hope in sending externally before the
rapid is for DPN, DPNCheck. diabetes. is to most as on DPNCheck moving complication common of peripheral Now peripheral diabetic test our which neuropathy, such the point-of-care neuropathies long-term or
technology. neuropathy goal is standard DPNCheck conduction nerve based the test study only point-of-care on peripheral
China been comprised has come from business sales partners. in sales the of market About DPNCheck Our Advantage U.S. distribution into a domestic DPNCheck XX% has Japan of and through Medicare and sales. revenue international BXB historically
their adoption the large commercial on medical systems Medicare Advantage Medicare increasing Advantage. team companies been are patients under where covered IDNs, and DPNCheck a We health a groups, in includes market. has have portion value-based substantial assessment health focused that This of
has past business over several been This years. growing the
However, the CMS substantial to hierarchical In or Centers announced policy calendar Medicare the injected and year, Advantage HCC Medicaid of risk year categories was due by the adjustment this or model XXXX. announced into changes significant Services condition April for for CMS. changes to uncertainty Medicare sector
the neuropathies screening medical programs, this codes led screening risk cleaning Advantage HAC that new uncertainty customer adjustment and DPNCheck their environment eliminated many peripheral believe essentially alters and detected including We Medicare programs. largest DPNCheck changes, or suspend The our by for are to model several for amongst DPNCheck. customers smaller using
Advantage-focused at alter away We necessary are and the one value-based to from landscape to be more move business will this evaluating broadly point, evolving Medicare our believe care. it strategy to addressing
that the strategy commercial new will quarter. is expectation Our finalize fourth our we during
help not do a to have flow a we we therefore, DPNCheck its operating saw caused business the Quell will the our revenues. take in and we time, line virtue by in Neurotherapeutics material Advantage DPNCheck which Medicare growing XXXX. will this a cash on reversal Nevertheless, pressure downward expect of changes As strategy continue new will investments Implementation quarter, business. positive offset of in the attractive generate margins, see
take prepared to And this that happy point. constitutes we'd questions at and be our comments,
